Breast Cancer Research and Treatment

, Volume 178, Issue 1, pp 121–133 | Cite as

A phase Ib, open-label, dose-escalation study of the safety and pharmacology of taselisib (GDC-0032) in combination with either docetaxel or paclitaxel in patients with HER2-negative, locally advanced, or metastatic breast cancer

  • Vandana G. AbramsonEmail author
  • Mafalda Oliveira
  • Andrés Cervantes
  • Hans Wildiers
  • Manish R. Patel
  • Todd M. Bauer
  • Philippe L. Bedard
  • Carlos Becerra
  • Stephen Richey
  • Michael C. Wei
  • Eric Reyner
  • John Bond
  • Na Cui
  • Timothy R. Wilson
  • Heather M. Moore
  • Cristina Saura
  • Ian E. Krop
Clinical trial



This open-label, phase Ib, dose-escalation, and dose-expansion study (NCT01862081) evaluated taselisib with a taxane in locally advanced or metastatic breast cancer (BC) and/or non-small cell lung cancer (NSCLC).


Patients received taselisib (2–6 mg tablet or 3–6 mg capsule) plus docetaxel or paclitaxel. Primary endpoints were safety, dose-limiting toxicities, maximum tolerated dose, and identification of a recommended phase II dose. Secondary endpoints included pharmacokinetics and antitumor activity assessment.


Eighty patients (BC: 72; NSCLC: 7; BC/NSCLC: 1) were enrolled (docetaxel-receiving arms: 21; paclitaxel-receiving arms: 59). Grade ≥ 3 adverse events (AEs), serious AEs, and AEs leading to death were reported in 90.5%, 42.9%, and 14.3% of patients, respectively (docetaxel-receiving arms), and 78.9%, 40.4%, and 3.5% of patients, respectively (paclitaxel-receiving arms). Eight patients experienced dose-limiting toxicities. The maximum tolerated dose was exceeded with 3 mg taselisib (capsule) for 21 consecutive days plus 75 mg/m2 docetaxel and not exceeded with 6 mg taselisib (tablet) for 5 days on/2 days off plus 80 mg/m2 paclitaxel. Objective response rates and clinical benefit rates were 35.0% and 45.0%, respectively (docetaxel-receiving arms), and 20.4% and 27.8%, respectively (paclitaxel-receiving arms). Exposure for paclitaxel or docetaxel plus taselisib was consistent with the single agents.


Taselisib in combination with a taxane has a challenging safety profile. Despite evidence of antitumor activity, the benefit–risk profile was deemed not advantageous. Further development is not planned.


Taselisib GDC-0032 PI3K PI3K inhibitor Metastatic breast cancer PIK3CA 



Adverse event


Adverse event group term


Adverse event of special interest


Area under the curve from time 0 to the last measurable concentration


Area under the curve during 24 h


Breast cancer


Clinical benefit rate


Confidence interval


Maximum observed plasma concentration


Minimum observed plasma concentration


Complete response


Circulating tumor DNA


Dose-limiting toxicity


Duration of response


Eastern Cooperative Oncology Group performance status


Estrogen receptor


Granulocyte-colony stimulating factor


Human epidermal growth factor receptor 2


Hormone receptor


Metastatic breast cancer


Medical Dictionary for Regulatory Activities


Mutation not detected


Maximum tolerated dose


Not evaluable


National Cancer Institute-Common Terminology Criteria for Adverse Events


Non-small cell lung cancer


Polymerase chain reaction


Progressive disease


Progression-free survival


Progesterone receptor


Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha


Phosphatidylinositol 3-kinase




Partial response


Phosphatase and tensin homolog






Every 3 weeks


Response Evaluation Criteria in Solid Tumors


Serious adverse event


Stable disease


Sum of the longest diameter


Time to maximum observed plasma concentration



We would like to thank the patients, their families, the nurses, and the investigators who participated in this study. The authors would like to thank Thomas J. Stout, PhD, Jerry Y. Hsu, MD, PhD, Jing He, MD, Alison Cardenas, RN, Deanna Wilson, MS, and Jiaheng Qiu, PhD (Genentech, Inc., South San Francisco, CA, USA), for input during the study. This study was funded by Genentech, Inc./F. Hoffmann-La Roche Ltd. F. Hoffmann-La Roche Ltd funded the study, provided study drugs, and was involved in the study design, protocol development, regulatory and ethics approvals, safety monitoring and reporting, data management, and data analysis and interpretation. Support for third-party writing assistance, furnished by Islay Steele, PhD, of Health Interactions, was provided by F. Hoffmann-La Roche Ltd.

Author contributions

VGA and IEK were involved in the conception and design of the study. VGA, MCW, and ER were involved in development of the methodology used. VGA, MO, AC, HW, MRP, TMB, PLB, CB, SR, HMM, CS, and IEK were involved in the acquisition of data (acquired and managed patients, provided facilities, etc.). HW, MCW, ER, JB, NC, TRW, and HMM were involved in analysis and interpretation of data (e.g., statistical analysis, biostatistics, computational analysis). MCW, ER, JB, NC, TRW, and HMM were involved in administrative, technical, or material support (i.e., reporting or organizing data, constructing databases). MCW was involved in study supervision. All authors were involved in the writing, review, and/or revision of this manuscript and approved the final manuscript.


This study was funded by Genentech, Inc./F. Hoffmann-La Roche Ltd. F. Hoffmann-La Roche Ltd funded the study, provided study drugs, and was involved in the study design, protocol development, regulatory and ethics approvals, safety monitoring and reporting, data management, and data analysis and interpretation.

Compliance with ethical standards

Conflict of interest

VGA has received research funding from Genentech, Astellas, and Lilly, and has consulted for Eisai and Novartis. MO has received remuneration from Roche, consulting or advisory fees from Roche, GSK, PUMA Biotechnology, and funding from AstraZeneca, Philips Healthcare, Genentech, Roche, Novartis, Immunomedics, Seattle Genetics, GSK, Boehringer-Ingelheim, PUMA Biotechnology (all to the Institution). AC has received consulting or advisory fees from Merck Serono, Roche, Beigene, Bayer, Servier, Lilly, Novartis, Takeda and Astelas, and funding from Genentech, Merck Serono, Roche, Beigene, Bayer, Servier, Lilly, Novartis, Takeda, Astelas, Fibrogen, Amcure, Sierra Oncology, Astra Zeneca, Medimmune, BMS, and MSD. HW has received travel support from Roche, TRM Oncology, Puma Biotechnology, and Pfizer (outside of the submitted work), and his institution has received consulting fees and honoraria from Roche, AstraZeneca, Amgen, Lilly, Novartis, AbbVie, Vifor Pharma, Pfizer, Celldex Therapeutics, Janssen-Cilag, TRM Oncology, Puma Biotechnology, Orion Corporation, and an unrestricted research grant from Roche (outside of the submitted work). MRP has received consulting or advisory fees from Exelixis, Pfizer, EMD Serono, Pharmacyclics, Genentech, and Celgene. TMB has received remuneration for employment Tennessee Oncology, remuneration for speakers’ bureau from Bayer (personal), remuneration for travel from Astellas Pharma, AstraZeneca, Celgene, Clovis Oncology, EMD Serono, Genentech, Lilly, Merck, Novartis, Ignyta, Pharmacyclics, Loxo, Bayer, Guardant Health, Moderna Therapeutics and Sysmex, consulting or advisory fees from Guardant Health (personal), Loxo (personal), Pfizer (personal), Leap Therapeutics (institutional), Ignyta (Institutional), Moderna Therapeutics (Institutional), Bayer (personal), Guardant Health and Pfizer (personal and Institutional), and Institutional funding from: Daiichi Sankyo, Medpacto, Inc., Incyte, Mirati Therapeutics, MedImmune, Abbvie, AstraZeneca, Leap Therapeutics, MabVax, Stemline Therapeutics, Merck, Lilly, GlaxoSmithKline, Novartis, Pfizer, Genentech/Roche, Deciphera, Merrimack, Immunogen, Millennium, Ignyta, Calithera Biosciences, Kolltan Pharmaceuticals, Principa Biopharma, Peleton, Immunocore, Aileron Therapeutics, Bristol-Myers Squibb, Amgen, Moderna Therapeutics, Sanofi, Boehringer Ingelheim, Astellas Pharma, Five Prime Therapeutics, Jacobio, Top Alliance BioScience, Loxo, Janssen, Clovis Oncology, Takeda, Karyopharm Therapeutics, Onyx, Phosplatin Therapeutics, Foundation Medicine and ARMO BioSciences and Bayer. PLB reports institutional grants from Bristol-Myers Squibb, Sanofi, AstraZeneca, Genentech/Roche, Servier, Merck, Nektar, Mersana, Novartis, GlaxoSmithKline, SignalChem, PTC Therapeutics (all during the conduct of the study), and is the current Chair of the Investigational New Drug Committee, Canadian Clinical Trials Group, an Executive Board Member for the Breast International Group, a Steering Committee Member for the American Association for Cancer Research Project GENIE, and a member of the NCI-BIO Breast Cancer Immunotherapy Task Force. CB has received honoraria from Taiho Pharmaceutical, consulting or advisory fees from SOBI, Ipsen, Takeda, Bayer, HERON, and Agenus, and fees from speakers’ bureau from Taiho Pharmaceutical, Bristol-Myers Squibb, and Celgene. SR has received remuneration from AstraZeneca, Genentech Inc., Genzyme Corporation, consulting or advisory fees from AstraZeneca, and funding from Acerta Pharma LLC, Eisai Inc., Eli Lilly and Company, EMD Serono, Inc., E.R. Squibb & Sons, L.L.C., Genentech, Inc., Ipsen Biopharmaceuticals, Inc., Janssen Research & Development, LLC., Janssen Research & Development, LLC., Novartis Pharmaceuticals Corporation, Tesaro, Inc. MCW, ER, JB, NC, TRW, and HMM are employees of Genentech and hold stock in Roche. CS has received travel grants from Puma Biotechnology, Pfizer, Roche, Astra Zeneca, Celgene, Daiichi Sankyo, Eisai, Genomyc Health, Novartis, Pierre Fabre, and Synthon Biopharmaceuticals, consulting or advisory fees from Puma Biotechnology, Pfizer, Roche, Astra Zeneca, Celgene, Daiichi Sankyo, Eisai, Genomyc Health, Novartis, Pierre Fabre, and Synthon Biopharmaceuticals, and funding from Roche-Genentech, Macrogenics, Pfizer, Piqur Therapeutics, Puma Biotechnology, Synthon Biopharmaceuticals, and Novartis. IEK has received grants and personal fees from Genentech/Roche (during the conduct of the study), grants from Pfizer, and personal fees from Macrogenics, Amgen, Taiho, Context Therapeutics, Seattle Genetics, and Daiichi Sankyo (outside of the submitted work). All authors received support for third-party writing assistance for this manuscript from Genentech, Inc./F. Hoffmann-La Roche Ltd.

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee (Supplementary methods) and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Informed consent

Informed consent was obtained from all individual participants included in the study.

Supplementary material

10549_2019_5360_MOESM1_ESM.docx (183 kb)
Supplementary material 1 (DOCX 184 kb)


  1. 1.
    National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®): Breast Cancer. Version 1. 2018. Accessed 12 Dec 2018
  2. 2.
    National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®): Non-Small Cell Lung Cancer. Version 5. 2018. Accessed 12 Dec 2018
  3. 3.
    Fossella FV, DeVore R, Kerr RN et al (2000) Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group. J Clin Oncol 18:2354–2362. CrossRefPubMedGoogle Scholar
  4. 4.
    Shepherd FA, Dancey J, Ramlau R et al (2000) Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol 18:2095–2103. CrossRefPubMedGoogle Scholar
  5. 5.
    Yuan TL, Cantley LC (2008) PI3K pathway alterations in cancer: variations on a theme. Oncogene 27:5497–5510. CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Engelman JA (2009) Targeting PI3K signalling in cancer: opportunities, challenges and limitations. Nat Rev Cancer 9:550–562. CrossRefPubMedGoogle Scholar
  7. 7.
    Fruman DA, Rommel C (2014) PI3K and cancer: lessons, challenges and opportunities. Nat Rev Drug Discov 13:140–156. CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Samuels Y, Wang Z, Bardelli A et al (2004) High frequency of mutations of the PIK3CA gene in human cancers. Science 304:554. CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Zhang Y, Ng PK, Kucherlapati M et al (2017) A pan-cancer proteogenomic atlas of PI3K/AKT/mTOR pathway alterations. Cancer Cell 31:820–832.e3. CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Cancer Genome Atlas Network (2012) Comprehensive molecular portraits of human breast tumours. Nature 490:61–70. CrossRefGoogle Scholar
  11. 11.
    Ciriello G, Gatza ML, Beck AH et al (2015) Comprehensive molecular portraits of invasive lobular breast cancer. Cell 163:506–519. CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Sabine VS, Crozier C, Brookes CL et al (2014) Mutational analysis of PI3K/AKT signaling pathway in tamoxifen exemestane adjuvant multinational pathology study. J Clin Oncol 32:2951–2958. CrossRefPubMedGoogle Scholar
  13. 13.
    Sarris EG, Saif MW, Syrigos KN (2012) The biological role of PI3K pathway in lung cancer. Pharmaceuticals (Basel) 5:1236–1264. CrossRefGoogle Scholar
  14. 14.
    Yamamoto H, Shigematsu H, Nomura M et al (2008) PIK3CA mutations and copy number gains in human lung cancers. Cancer Res 68:6913–6921. CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Wang L, Hu H, Pan Y et al (2014) PIK3CA mutations frequently coexist with EGFR/KRAS mutations in non-small cell lung cancer and suggest poor prognosis in EGFR/KRAS wildtype subgroup. PLoS ONE 9:e88291. CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Barlesi F, Mazieres J, Merlio JP et al (2016) Routine molecular profiling of patients with advanced non-small-cell lung cancer: results of a 1-year nationwide programme of the French Cooperative Thoracic Intergroup (IFCT). Lancet 387:1415–1426. CrossRefPubMedGoogle Scholar
  17. 17.
    Panagiotou I, Tsiambas E, Lazaris AC et al (2012) PTEN expression in non small cell lung carcinoma based on digitized image analysis. J BUON 17:719–723PubMedGoogle Scholar
  18. 18.
    Olivero AG, Heffron TP, Baumgardner M et al (2013) Discovery of GDC-0032: a beta-sparing PI3K inhibitor active against PIK3CA mutant tumors. Cancer Res. CrossRefGoogle Scholar
  19. 19.
    Wallin JJ, Edgar KA, Guan J et al (2013) The PI3K inhibitor GDC-0032 is selectively potent against PIK3CA mutant breast cancer cell lines and tumors. Cancer Res. CrossRefGoogle Scholar
  20. 20.
    Ndubaku CO, Heffron TP, Staben ST et al (2013) Discovery of 2-{3-[2-(1-isopropyl-3-methyl-1H-1,2-4-triazol-5-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepin-9-yl]-1H-pyrazol-1-yl}-2-methylpropanamide (GDC-0032): a β-sparing phosphoinositide 3-kinase inhibitor with high unbound exposure and robust in vivo antitumor activity. J Med Chem 56:4597–4610. CrossRefPubMedGoogle Scholar
  21. 21.
    Edgar KA, Song K, Schmidt S et al (2016) The PI3K inhibitor, taselisib (GDC-0032), has enhanced potency in PIK3CA mutant models through a unique mechanism of action. Cancer Res. CrossRefGoogle Scholar
  22. 22.
    Sampath D, Nannini MA, Jane G et al (2013) The PI3K inhibitor GDC-0032 enhances the efficacy of standard of care therapeutics in PI3K alpha mutant breast cancer models. Cancer Res. CrossRefGoogle Scholar
  23. 23.
    Juric D, Krop I, Ramanathan RK et al (2017) Phase I dose-escalation study of taselisib, an oral PI3K inhibitor, in patients with advanced solid tumors. Cancer Discov 7:704–715. CrossRefPubMedPubMedCentralGoogle Scholar
  24. 24.
    Bendell JC, Rodon J, Burris HA et al (2012) Phase I, dose-escalation study of BKM120, an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors. J Clin Oncol 30:282–290. CrossRefPubMedGoogle Scholar
  25. 25.
    Gopal AK, Kahl BS, de Vos S et al (2014) PI3Kδ inhibition by idelalisib in patients with relapsed indolent lymphoma. N Engl J Med 370:1008–1018. CrossRefPubMedPubMedCentralGoogle Scholar
  26. 26.
    Sarker D, Ang JE, Baird R et al (2015) First-in-human phase I study of pictilisib (GDC-0941), a potent pan-class I phosphatidylinositol-3-kinase (PI3K) inhibitor, in patients with advanced solid tumors. Clin Cancer Res 21:77–86. CrossRefPubMedGoogle Scholar
  27. 27.
    Faber KP, Borin MT, Cheeti S et al (2016) Impact of formulation and food on taselisib (GDC-0032) bioavailability: powder-in-capsule formulation represents unique drug development challenge. Clin Pharmacol Ther. CrossRefGoogle Scholar
  28. 28.
    Saura C, de Azambuja E, Hlauschek D et al (2017) Primary results of LORELEI: a phase II randomized, double-blind study of neoadjuvant letrozole (LET) plus taselisib versus LET plus placebo (PLA) in postmenopausal patients (pts) with ER +/HER2-negative early breast cancer (EBC). Ann Oncol. CrossRefGoogle Scholar
  29. 29.
    Baselga J, Dent SF, Cortés J et al (2018) Phase III study of taselisib (GDC-0032) + fulvestrant (FULV) v FULV in patients (pts) with estrogen receptor (ER)-positive, PIK3CA-mutant (MUT), locally advanced or metastatic breast cancer (MBC): primary analysis from SANDPIPER. J Clin Oncol. CrossRefPubMedPubMedCentralGoogle Scholar
  30. 30.
    Dickler MN, Saura C, Richards D et al (2018) Phase II study of taselisib (GDC-0032) in combination with fulvestrant in patients with HER2-negative, hormone receptor-positive advanced breast cancer. Clin Cancer Res 24:4380–4387. CrossRefPubMedPubMedCentralGoogle Scholar
  31. 31.
    Kenmotsu H, Tanigawara Y (2015) Pharmacokinetics, dynamics and toxicity of docetaxel: why the Japanese dose differs from the Western dose. Cancer Sci 106:497–504. CrossRefPubMedPubMedCentralGoogle Scholar
  32. 32.
    Huizing M, Vermorken J, Rosing H et al (1995) Pharmacokinetics of paclitaxel and three major metabolites in patients with advanced breast carcinoma refractory to anthracycline therapy treated with a 3-hour paclitaxel infusion: a European Cancer Centre (ECC) trial. Ann Oncol 6:699–704. CrossRefPubMedGoogle Scholar
  33. 33.
    Paridaens R, Biganzoli L, Bruning P et al (2000) Paclitaxel versus doxorubicin as first-line single-agent chemotherapy for metastatic breast cancer: a European Organization for Research and Treatment of Cancer Randomized Study with cross-over. J Clin Oncol 18:724–733. CrossRefPubMedGoogle Scholar
  34. 34.
    Martín M, Chan A, Dirix L et al (2016) A randomized adaptive phase II/III study of buparlisib, a pan-class I PI3K inhibitor, combined with paclitaxel for the treatment of HER2–advanced breast cancer (BELLE-4). Ann Oncol 28:313–320. CrossRefGoogle Scholar
  35. 35.
    Vuylsteke P, Huizing M, Petrakova K et al (2016) Pictilisib PI3Kinase inhibitor (a phosphatidylinositol 3-kinase [PI3K] inhibitor) plus paclitaxel for the treatment of hormone receptor-positive, HER2-negative, locally recurrent, or metastatic breast cancer: interim analysis of the multicentre, placebo-controlled, phase II randomised PEGGY study. Ann Oncol 27:2059–2066. CrossRefPubMedGoogle Scholar
  36. 36.
    Sharma P, Abramson VG, O’Dea A et al (2018) Clinical and biomarker results from phase I/II study of PI3K inhibitor BYL 719 (alpelisib) plus nab-paclitaxel in HER2-negative metastatic breast cancer. J Clin Oncol. CrossRefPubMedPubMedCentralGoogle Scholar
  37. 37.
    Staben ST (2017) Discovery of GDC-0077, a highly isoform selective inhibitor of PI3Kα that promotes selective loss of mutant-p110α. Cancer Res. CrossRefGoogle Scholar
  38. 38.
    Isakoff SJ, Bendell JC, Cervantes A et al (2015) Phase Ib dose-escalation study of an Akt inhibitor ipatasertib (Ipat) in combination with docetaxel (Doc) or paclitaxel (Pac) in patients (pts) with metastatic breast cancer (MBC). Cancer Res.
  39. 39.
    Dent R, Im S, Espie M et al (2018) Overall survival (OS) update of the double-blind placebo (PBO)-controlled randomized phase 2 LOTUS trial of first-line ipatasertib (IPAT) + paclitaxel (PAC) for locally advanced/metastatic triple-negative breast cancer (mTNBC). J Clin Oncol. CrossRefGoogle Scholar
  40. 40.
    Kim S, Dent R, Im S et al (2017) Ipatasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (LOTUS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Oncol 18:1360–1372. CrossRefPubMedPubMedCentralGoogle Scholar
  41. 41.
    Schmid P, Abraham J, Chan S et al (2018) AZD5363 plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (PAKT): a randomised, double-blind, placebo-controlled, phase II trial. J Clin Oncol. CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  • Vandana G. Abramson
    • 1
    Email author
  • Mafalda Oliveira
    • 2
  • Andrés Cervantes
    • 3
  • Hans Wildiers
    • 4
  • Manish R. Patel
    • 5
    • 6
  • Todd M. Bauer
    • 6
  • Philippe L. Bedard
    • 7
  • Carlos Becerra
    • 8
  • Stephen Richey
    • 9
  • Michael C. Wei
    • 10
  • Eric Reyner
    • 11
  • John Bond
    • 12
  • Na Cui
    • 13
  • Timothy R. Wilson
    • 14
  • Heather M. Moore
    • 14
  • Cristina Saura
    • 2
  • Ian E. Krop
    • 15
  1. 1.Vanderbilt University Medical CenterNashvilleUSA
  2. 2.Department of Medical Oncology, Vall d’Hebron University HospitalVall d’Hebron Institute of Oncology (VHIO)BarcelonaSpain
  3. 3.CIBERONC, Medical Oncology Department, Institute of Health Research INCLIVAUniversity of ValenciaValenciaSpain
  4. 4.Department of General Medical Oncology, University Hospitals LeuvenLeuven Cancer InstituteLouvainBelgium
  5. 5.Florida Cancer Specialists/Sarah Cannon Research InstituteSarasotaUSA
  6. 6.Sarah Cannon Research Institute/Tennessee Oncology, PLLCNashvilleUSA
  7. 7.Division of Medical Oncology & Hematology, Department of Medicine, Princess Margaret Cancer Centre, University Health NetworkUniversity of TorontoTorontoCanada
  8. 8.US Oncology NetworkTexas OncologyDallasUSA
  9. 9.US Oncology NetworkTexas OncologyFort WorthUSA
  10. 10.Product Development OncologyGenentech, Inc.South San FranciscoUSA
  11. 11.Department of Clinical PharmacologyGenentech, Inc.South San FranciscoUSA
  12. 12.PDSS-Global Safety Risk Management Oncology GroupGenentech, Inc.South San FranciscoUSA
  13. 13.CStone PharmaceuticalsSuzhouChina
  14. 14.Oncology Biomarker DevelopmentGenentech, IncSouth San FranciscoUSA
  15. 15.Dana-Farber Cancer InstituteBostonUSA

Personalised recommendations